DPP4 and hydrops fetalis: To date, it is very unlikely that dipeptidyl peptidase-4 inhibitors have a clinically important cardiorenal benefits (Fig. 1): residual risk is 99% for MACE, 100% for kidney outcomes (excluding new albuminuria) [15], and 100% for HF [13].